CD33 (CD33 Molecule)

Genetic and transcriptomic evidence jointly support the concept of a myeloid-inflammation axis in PCOS. The inverse MR association for absolute monocyte count alongside positive risk for CD33+HLA-DR+ compartments, together with cross-cohort evidence of myeloid enrichment and inflammatory pathway activation, is compatible with a potential mechanistic link between immune imbalance and PCOS and provides a hypothesis-generating framework for future therapeutic investigation.

TCF3::HLF-positive B-ALL represents an ultra-high-risk leukemia requiring allo-HSCT for long-term remission. CAR-T serves as a bridge to transplantation, while RAS and CD33-directed therapies warrant further investigation. These findings provide critical insights into disease biology and potential treatment.

In this review, we will describe the current status of CAR T/NK cell development for AML. We will also introduce a new CAR T-cell or NK-cell therapy that targets mismatched HLA-DRB1 in patients with AML who have relapsed following an allogeneic haematopoietic stem cell transplant.

Furthermore, the addition of CD33xCD28 IgG4-scFv2 showed faster time to cell attachment, increased lytic events, and improved specificity towards double-target expressing cells. In summary, the data indicate that combining co-stimulation via a second tumor-associated antigen to CD3-TCEs enhances T-cell lytic activity and simultaneously increases specificity against double-target expressing AML cells.

These platforms enable rapid, multiplexed biomarker analysis of fusion genes (BCR-ABL, PML-RARA), surface antigens (CD33/CD34), exosomes, and CTCs for minimally invasive leukemia detection, MRD monitoring, and remote management. Covering principles, material advances, clinical applications, and prospects, this work highlights their potential to revolutionize accessible, precise, timely global leukemia care.

A combination that has become standard of care is HMA plus venetoclax for patients unfit for intensive chemotherapy, achieving high remission rates with relatively manageable toxicity...Clinical decision-making requires rapid molecular diagnostic testing, assessment of a patient's fitness for intensive chemotherapy, and management of toxicities and drug interactions. This narrative review, illustrated with patient vignettes, summarizes currently available therapies, guides through the latest trials on frontline combinations in AML, and provides a preview of how the therapeutic landscape may evolve in the near future.

Moreover, we demonstrate that AdFITC-TCE plus fluoresceinated adaptors and T-cells inhibit acute myeloid leukemia cell growth in NSG mice in vivo with similar efficacy as AdFITC-CAR T-cells. Together, this data suggests that AdFITC-TCE, in combination with any given fluoresceinated binder, might be a versatile tool to activate T-cells, leading to respective target cell lysis.

P=N/A, N=165, Recruiting, Pfizer | Trial completion date: Apr 2027 --> Jul 2027 | Trial primary completion date: Apr 2027 --> Jul 2027

P2, N=40, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Jul 2027 --> Jul 2028

Antigenic shifts affecting megakaryocytic, myeloid, progenitor-associated, and lymphoid markers are common after chemotherapy. For MRD assessment, the use of more specific megakaryocytic markers such as CD110, together with comprehensive multiparameter flow cytometry panels, may improve detection accuracy.

Multidimensional technological innovation and the synergistic optimization of combination therapies are critical to overcoming AML-specific barriers. These advances hold the potential to unlock the precise clinical application of CAR-T therapy, ultimately improving survival outcomes for patients with relapsed/refractory AML.

This modular platform addresses critical limitations in enzymatic synthesis of modified sialosides and their efficient display on therapeutic cells. Our work establishes a versatile and practical platform for developing next-generation immunotherapies that precisely target the Sia-Siglec axis with improved specificity and functionality.